Uncategorized
No direct correlation with adverse events found for bevacizumab treatment of ROP
VIENNA —The use of intravitreal bevacizumab appears to be safe in preterm infants for treatment of retinopathy of prematurity, according to a long-term multicenter study. The 9-year study performed in Mexico, Chile and India focused on systemic and adverse events, and included 418 eyes of 262 infants. Mean weight at birth was 1,338.3 grams, ranging from 600 grams to 1,800 grams. Average age at time of birth was 30 weeks, and average age at time of treatment was 36 weeks.